Nogo-A Antibody - new trial has started
The purpose of the NISCI trial, was to test if an antibody therapy (anti-Nogo-A) can improve movement and quality of life of tetraplegic patients. Previous trial showed that this treatment is safe and well accepted. Moreover, the last multicenter, multinational, placebo controlled phase-II study was conducted in several European countries such as Switzerland, Germany, Italy, Spain and the Czech Republic.
Publications
- Weidner N, Abel R, Maier D, Röhl K, Röhrich F, Baumberger M, Hund-Georgiadis M, Saur M, Benito J, Rehahn K, Aach M, Badke A, Kriz J, Barkovits K, Killeen T, Farner L, Seif M, Hubli M, Marcus K, Maurer MA, Robert B, Rupp R, Scheuren PS, Schubert M, Schuld C, Sina C, Steiner B, Weis T, Hug A, Bolliger M, Weiskopf N, Freund P, Hothorn T, Schwab ME, Curt A; Nogo Inhibition in Spinal Cord Injury Study Group. Safety and efficacy of intrathecal antibodies to Nogo-A in patients with acute cervical spinal cord injury: a randomised, double-blind, multicenter, placebo-controlled, phase 2b tiral. Lancet Neurol. 2025 Jan: 24(1):42-53. DOI: 10.1016/S1474-4422(24)00447-2
- Kucher K, Johns D, Maier D, Abel R, Badke A, Baron H, Thietje R, Casha S, Meindl R, Gomez-Mancilla B, Pfister C, Rupp R, Weidner N, Mir A, Schwab ME, Curt A. First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury. Neurorehabil Neural Repair. 2018 Jun;32(6-7):578-589. Epub 2018 Jun 5.DOI: 10.1177/1545968318776371
The SPROUT trial has started
We are recruiting individuals with acute spinal cord injury of the cervical spine and investigating the tolerability and safety of the NG004 antibody.
The SPROUT trial is investigating an antibody (NG004) to demonstrate its safety and tolerability in the regeneration of damaged nerve fibers. The benefit is that treatment with NG004 may improve movement, bodily functions (e.g. bladder) and sensation and/or alleviate symptoms. The SPROUT trial is a multicenter, multinational phase-I which is conducted in Germany and Switzerland.
For further information:
Email: sprout@balgrist.ch
novaGo therapeutics, Schlieren, Switzerland: https://www.novagotherapeutics.com